Imagine trying to save a child's life in a village where the nearest hospital is hours away. This project tests if a simple rectal medication given by a local health worker can bridge the gap until a child reaches a clinic. It compares different combinations of these medicines to find the safest and most effective way to stop deaths in remote areas.
High child mortality in remote areas due to the lack of transport and infrastructure required for injectable malaria treatments. Current gold-standard care is often unreachable, leaving a gap in timely treatment.
A clinical evidence base and a set of policy recommendations comparing two treatment regimens for severe malaria in remote settings.
If you are a drug manufacturer dealing with low uptake of specialized antimalarials — this project developed evidence on the efficacy of rectal artesunate (RAS) and ACTs that can justify scaling production for remote markets. This could help capture a market serving children under 5 in Africa.
If you are a logistics provider dealing with the difficulty of delivering injectable drugs to remote areas — this project developed a model for using RAS and RDTs via community health workers. This allows for a shift toward more stable, easier-to-transport medication formats.
If you are a consultancy dealing with inefficient malaria mortality rates — this project developed sustainable policy recommendations based on real-world data from DRC and Zambia. This provides a blueprint for implementing integrated community case management.
Based on available project data, specific pricing or cost per dose is not provided; however, the project aims to address the 'cost' barrier that currently limits access to care.
The project focuses on the feasibility of delivery via community health workers in two districts of DRC and Zambia, providing the evidence needed for wider national or regional rollout.
Based on available project data, there is no mention of patents; the focus is on observational study results and policy recommendations for existing drug combinations.
The project specifically assesses and mitigates institutional barriers among regulators and malaria experts to recommend sustainable policies.
The project runs from 2023-04-01 to 2027-03-31.
The consortium is purely academic and non-profit, consisting of 5 partners across 5 countries. It is led by the University of Antwerp and includes specialized research entities like Medicines for Malaria Venture and national institutes from DRC, Zambia, and Tanzania. With 0% industry participation, the project is driven by clinical evidence and public health goals rather than immediate commercial product development.
Contact the University of Antwerp research office regarding the SEMA ReACT project.
Contact us to find partners for implementing these malaria treatment protocols in new regions.
